Cite
HARVARD Citation
Cuvier, V. et al. (2018). A first‐in‐man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM‐1 receptor inhibition. British journal of clinical pharmacology. pp. 2270-2279. [Online].